ARTICLE | Clinical News

J&J six-week combo cures all HCV patients in Phase II cohort

September 23, 2016 7:00 AM UTC

All 20 patients receiving a six-week course of a triple-combination therapy from Johnson & Johnson (NYSE:JNJ) to treat HCV genotype 1 infection achieved an SVR12 in a Phase II study, according to J&J's partners Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) and Medivir AB (SSE:MVIR B). Data were presented at the European Association for the Study of the Liver (EASL) meeting in Paris.

The cohort, one of four in the study, received a combination including J&J's Olysio simeprevir and AL-335, plus Achillion's odalasvir ( ACH-3102). J&J holds rights to Olysio from Medivir. It obtained AL-335 via its acquisition of Alios Biopharma Inc. in 2014, and received exclusive, worldwide rights to odalasvir in a May 2015 deal (see BioCentury, May 25, 2015). ...